← Retour à la une
Océanie · Agences & temps réel · AAP

Arizona Veterans Research and Education Foundation in support of Phoenix VA Health Care System and Young Blood Institute Announce Cooperative Research and Development Agreement ...

Publié par AAP · Australie il y a 18 h

Résumé détaillé

AmBARI Healthcare, Inc., The Phoenix VA Health Care System, the Arizona Veterans Research and Education Foundation, and the Young Blood Institute (YBI), a 501 (c) (3) non-profit…

PHOENIX, Nov. 20, 2026 /PRNewswire/ -- AmBARI Healthcare, Inc., The Phoenix VA Health Care System, the Arizona Veterans Research and Education Foundation, and the Young Blood Institute (YBI), a 501(c)(3) non-profit Clinical Research Organization, today announced the execution of a Principal Investigator-Initiated Cooperative Research and Development Agreement (CRADA) to conduct a pilot clinical study evaluating optimized Therapeutic Plasma Exchange (TPE) in Veterans with mild cognitive impairment (MCI) and prodromal Alzheimer's disease.

The AmβARI study (VA Protocol #1859907) is a randomized, controlled trial that will enroll up to 56 veterans. It will assess an extended full-volume TPE protocol. The primary endpoint will be brain imaging (PET-CT) using the NAV-4694 tracer to quantify changes in brain burden of amyloid. The study is led by Principal Investigator, S. Mitchell Harman, MD, PhD, at the Phoenix VA Health Care System. Dr. Harman designed the VA AmβARI study protocol in collaboration with the Young Blood Institute and AmβARI Healthcare Global Principal Investigator, Colin Masters, MD, and other members of the AmβARI/YBI investigative team. AmβARI Healthcare, Inc.

Both the Grifols AMBAR trial and real-world experience at Ace Alzheimer Center Barcelona have demonstrated a 61% success rate in delaying or arresting disease progression in early to moderate Alzheimer's patients, with 11–15% of patients showing memory improvement. AMBAR studied 498 patients, while Ace Barcelona has now delivered over 2,100 full-volume TPE procedures as standard clinical care. YBI's own pre-clinical studies have also demonstrated the ability of TPE to clear Amyloid Beta in cognitively unimpaired subjects. YBI and Ace have collaborated on protocol optimization for this study.

Elijah J. Ditter, Medical Center Director of the Phoenix VA Health Care System, stated: "This CRADA represents an important step in our ongoing efforts to bring innovative, translational research directly to our…

Début de l'article, extrait de AAP. Pour lire la suite, ouvrez l'article chez le média.

Lire l'article complet sur AAP Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.aap.com.au)